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Abstract
Background: Few clinical studies have assessed Rho kinase (ROCK) in patients with dia-
betes mellitus (DM) and ST-segment elevation myocardial infarction (STEMI). This study 
aimed to determine whether ROCK activity in circulating leukocytes is increased in STEMI 
patients with DM and whether ROCK activity predicts the onset of cardiovascular events.
Methods: Blood samples were collected from 60 STEMI patients, divided into non-diabetes 
mellitus (NDM) and DM groups. Main outcome measures were all-cause mortality, readmis-
sion for acute coronary syndrome (ACS), congestive heart failure (CHF), or stroke from pres-
entation to approximately 5 years (mean: 41.3 ± 19.6 months; range: 3–60 months).
Results: Compared with the NDM group (n = 34), ROCK1 activity was greater in the DM 
group (n = 26) (33.14 ± 11.31 vs. 26.24 ± 11.06, p = 0.021), while ROCK2 activity was not 
different between the groups. There occurred 3 deaths, and 10 readmissions with ACS, 4 with 
CHF and 2 with stroke during the follow-up period. Patients with a high ROCK1 activity on 
admission had a 3-fold risk of cardiovascular events (RR 3.15, 95% CI 1.04–9.58) compared 
with those with low ROCK1 activity. Patients with history of stroke had almost a 4-fold risk of 
cardiovascular events (RR 3.74; 95% CI 1.02–13.80).
Conclusions: ROCK1 activity was increased in STEMI patients with DM, which suggests 
that ROCK1 activity may be a useful diagnostic and prognostic marker of cardiovascular 
events for these patients. ROCK1 activity might help identify a subset of STEMI patients at 
particularly high risk. (Cardiol J 2016; 23, 4: 456–464)
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Introduction
Recent evidence increasingly suggests that 
the Rho/Rho kinase (ROCK) system may be in-
volved in the pathogenesis of acute coronary 
syndrome (ACS) [1, 2]. Preclinical studies showed 
that inhibition of the Rho/ROCK pathway can limit 
early atherosclerotic plaque development and re-
duce the size of ischemic-reperfusion injury [3]. 
Furthermore, ROCK is involved in the regulation 
of insulin signaling and glucose metabolism [4]. 
These findings indicate that ROCK is the key in 
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pathogenesis of coronary heart disease (CHD) and 
diabetes mellitus (DM). It is well known that DM 
is regarded as a CHD risk equivalent [5], and 31% 
of CHD patients suffer from DM [6].
The risk of death or new ischemic events var-
ies widely in patients with ACS. Several factors 
have been proposed to assess risk among ACS 
patients, including cardiac biomarkers. A recent 
study showed that ROCK activity was increased 
in patients with ACS, particularly in those with 
myocardial infarction (MI), and the combined usage 
of both ROCK activity and N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) might identify 
ACS patients at particularly high risk [7].
Clinical studies linking ROCK activity in ST-
-segment elevation myocardial infarction (STEMI) 
patients with DM are lacking. Therefore, the pre-
sent study aimed to investigate whether ROCK 
activity is elevated in STEMI patients with DM, 
determine the factors associated with increased 
ROCK activity in STEMI, and determine whether 
ROCK activity can be useful as a prognostic marker 
for patients with STEMI.
Methods
Study subjects
We prospectively enrolled 60 consecutive pa-
tients, who were diagnosed as STEMI according to 
the universal definition of MI [8], at the Cardiovas-
cular Center of Beijing Friendship Hospital, Capital 
Medical University, between August 2010 and July 
2011 (onset time of STEMI: a mean of 4.47 ± 3.16 h; 
range 0.5–12 h). Exclusion criteria included patients 
who had acute heart failure (HF) (Killip III or IV), 
cardiomyopathy, or valvular heart diseases. Due 
to the fact that statins could affect ROCK activity 
through modulation of Rho [9], patients taking statins 
before enrollment were also excluded. Patients were 
divided into non-diabetes mellitus (NDM) and DM 
groups based on the American Diabetes Association 
guideline [10]. All the patients were followed up for 
a mean of 41.3 ± 19.6 months, range 3–60 months, 
or until the occurrence of cardiovascular composite 
endpoint events (all-cause mortality, readmission 
with ACS, admission with congestive HF or stroke). 
Written informed consents were obtained from all 
subjects. The study protocol was approved by the 
Human Research Subjects Review Committee of the 
Beijing Friendship Hospital.
Study parameters
Age, sex, body mass index (BMI), waist cir-
cumference, blood pressure on admission, smoking 
status and concurrent basal diseases (hyperten-
sion, stroke and old MI) were recorded. Some 
biochemical parameters inflammatory parameters, 
and oxidative stress parameters (nitric oxide 
[NO], superoxide dismutase [SOD], and malon-
dialdehyde [MDA]) were assessed in venous 
blood samples after 8 h or overnight fasting. NO, 
SOD and MDA were all measured by chemical 
colorimetry. Angiography was performed on all 
patients to record the number of atherosclerotic 
vessels and luminal stenosis for Gensini score 
calculations. Echocardiograms were obtained to 
evaluate left ventricular function. Left ventricular 
end-diastolic diameter (LVEDD), left ventricular 
end-systolic diameter (LVESD), and left ven-
tricular ejection fraction (LVEF) were measured. 
All measurements were performed according to 
the recommendations of the American Society of 
Echocardiography.
Assay for ROCK expression and activity
Leukocytes were isolated from the 20 mL 
arterial blood samples that were drawn from each 
subject before primary percutaneous coronary 
intervention. Samples were stored at –80°C and 
tested together. Protein content of the samples was 
determined by Bradford assay (Biomed, China). 
Equal amounts of extracted proteins were sepa-
rated by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and transferred 
to a nitrocellulose membrane (Pierce). The primary 
antibodies were anti-ROCK1 monoclonal antibody 
(Santa Cruz), anti-ROCK2 monoclonal antibody 
(Santa Cruz) and anti-GAPDH antibody (Santa 
Cruz). Primary antibodies were diluted in block-
ing solution (1:500). Nitrocellulose membranes 
were incubated with primary antibody overnight 
at 4°C. After washing, blots were incubated with 
secondary antibody and specific binding was de-
tected using enhanced chemiluminescence with 
exposure to Kodak film. Bands were visualized 
with the use of the ECL detection kit (Amersham 
Pharmacia Biotech). ROCK activity was assayed 
using a Rho-associated kinase (ROCK1, ROCK2) 
Activity Assay kit following the manufacturer’s 
instructions (Genmed).
Statistical analysis
The statistical software pack SPSS 19.0 (SPSS 
Inc., IBM Company) was employed for statistical 
processing. The qualitative data were analyzed 
by c2 analysis. Independent-sample t-test was 
performed for comparison of parametric continu-
ous variables for the intergroup difference. Linear 
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correlation analysis was used to assess the relation 
between parametric variables and ROCK activity. 
Multivariate Cox regression analysis, using the 
enter method, was used to identify independent 
predictors of clinical endpoints. Event rates for 
clinical outcomes were also determined using the 
Kaplan-Meier method and compared using the log-
rank test. Data were expressed as mean ± stan- 




A total of 60 consecutive patients, who were 
not undergoing statin treatment, were diagnosed 
with STEMI: 49 males and 11 females. The patients 
were divided into two groups: non-diabetes mellitus 
(NDM; n = 34) and diabetes mellitus (DM; n = 26). 
Baseline clinical characteristics and laboratory pa-
rameters of both groups are summarized in Table 1.
Compared with the NDM group, the average 
age, sex, hypertension, stroke, old MI, percentage 
of smokers, BMI, waist circumference, systolic 
and diastolic blood pressure, heart rate, peak tro-
ponin T (cTnT), peak creatine kinase isoenzyme 
MB (CK-MB), and lipid level in DM group were 
similar. Admission blood glucose and glycosylated 
hemoglobin (HbA1c), as well as plasma high sen-
sitivity C-reactive protein (hs-CRP) levels were 
greater in the DM group compared with those in 
the NDM group, but white blood cell count (WBC), 
and erythrocyte sedimentation rate (ESR) were 
similar in both groups. The MDA plasma level 
was greater and SOD level was lower in the DM 
group. There were no significant between-group 
differences for the NO level, but it tended to be 
lower in the DM group.
There were no significant differences in echo-
cardiographic left ventricular dimensions between 
the groups, but patients had lower LVEF in the DM 
group. The coronary angiography results showed 
that the coronary triple-vessel changes and left 
main lesion were more frequent in the DM group. 
The Gensini score was higher in the DM group, 
however the difference was not significant.
ROCK activity and expression  
of ROCK1 and ROCK2
Compared with NDM group, ROCK1 activ-
ity was significantly increased in the DM group 
(33.14 ± 11.31 vs. 26.24 ± 11.06, p = 0.021), and 
there were no between-group differences regarding 
ROCK2 activity (14.03 ± 7.91 vs. 11.87 ± 7.45, 
p = 0.283; Fig. 1). However, protein levels of 
ROCK1 and ROCK2 were both greater in the DM 
group than in the NDM group (Fig. 2A–C).
Independent predictors of ROCK1 activity 
in STEMI patients with DM
To determine whether ROCK1 activity is 
a novel marker for DM and atherosclerosis, we 
performed an association analysis to determine 
the correlation coefficient of ROCK1 activity with 
LVEF, Gensini score, peak cTnT, peak CK-MB, 
NO, SOD, MDA, ESR, WBC, hs-CRP, HbA1c. The 
HbA1c and ROCK1 activity had a positive correla-
tion (Pearson correlation = 0.358, p = 0.008). None 
of the other factors was positively associated with 
increased levels of ROCK1 activity.
Multivariate predictors of clinical endpoint
There were 3 deaths, 10 readmissions with 
ACS, 4 admissions with congestive HF and 2 with 
stroke during the follow-up period. Table 2 shows 
the comparison of baseline clinical characteristics 
(including concomitant therapy) between no event 
and event groups. Factors such as DM (p = 0.002), 
stroke (p = 0.003), HbA1c (p = 0.048), peak cTnT 
(p = 0.015), and ROCK1 activity (p = 0.016) were 
significantly different between groups.
ROCK1 activity as a predictor of prognosis
The cutoff value of ROCK1 activity was 
26.41 μmol NADH/mg × min (median of ROCK1 
activity) in our study population. Multivariate re-
gression models showed that high ROCK1 activity 
on admission (RR 1.04, 95% CI 1.00–1.08), peak 
cTnT (RR 1.25, 95% CI 1.07–1.46), and stroke 
history (RR 11.51, 95% CI 2.50–53.04) were inde-
pendent predictors for long-term cardiovascular 
endpoints. Although patients with DM had a 2-fold 
risk of cardiovascular and cerebrovascular events 
when compared to those without DM, there were no 
significant differences between groups (Table 3). As 
demonstrated by the Kaplan-Meier survival curves 
(Fig. 3), patients with a high ROCK1 activity on 
admission had a 3-fold risk of a cardiovascular and 
cerebrovascular events compared with those with 
low ROCK1 activity (log rank = 8.800, p = 0.003).
Discussion
Increased ROCK1 activity  
in STEMI patients with DM
Some observations regarding the role of the 
Rho/ROCK signaling pathway in humans indicate 
that systemic activation of ROCK is associated with 
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many cardiovascular diseases [11, 12]. Additionally, 
it has been reported that ROCK activity is associat-
ed with the number of components of the metabolic 
syndrome [13] and inflammation markers such as 
CRP and adiponectin. Some studies have found that 
the Rho/ROCK signaling pathway is abnormally 
Table 1. Baseline characteristics of non-diabetes mellitus (NDM) and diabetes mellitus (DM) groups.
Baseline characteristic NDM (n = 34) DM (n = 26) P
Age [years] 59.94 ± 11.19 63.88 ± 10.45 0.169
Sex [male] 29 (85.3%) 20 (76.9%) 0.406
Medical history:
Hypertension 24 (70.6%) 14 (53.8%) 0.182
Old myocardial infarction 4 (11.8%) 5 (19.2) 0.422
Stroke 2 (5.9%) 5 (19.2%) 0.234
Smoking 24 (70.6%) 19 (73.1%) 0.832
Clinical tests:
Body mass index [kg/m2] 24.75 ± 5.35 24.95 ± 4.04 0.873
Waist circumference [cm] 95.40 ± 10.21 92.82 ± 9.70 0.381
Systolic BP [mm Hg] 125.90 ± 21.44 126.15 ± 18.02 0.963
Diastolic BP [mm Hg] 74.16 ± 13.18 73.35 ± 9.74 0.795
Heart rate [bpm] 80.03 ± 14.38 75.92 ± 13.13 0.269
LVEDD [cm] 5.32 ± 0.46 5.47 ± 0.64 0.321
LVESD [cm] 3.76 ± 0.61 4.08 ± 0.79 0.100
LVEF [%] 56.11 ± 9.30 49.81 ± 11.23 0.029*
Laboratory tests:
TC [mmol/L] 4.63 ± 0.89 4.68 ± 0.86 0.840
TG [mmol/L] 1.72 ± 0.73 2.32 ± 2.18 0.162
LDL-C [mmol/L] 2.57 ± 0.54 2.44 ± 0.49 0.353
HDL-C [mmol/L] 0.99 ± 0.21 0.96 ± 0.18 0.608
APG [mmol/L] 7.91 ± 1.99 11.32 ± 4.91 0.001**
HbA1c [%] 5.72 ± 0.50 7.96 ± 1.60 0.000**
WBC [×109/L] 10.99 ± 3.64 10.40 ± 2.60 0.488
ESR [mm/1 h] 11.00 ± 15.7 9.77 ± 6.69 0.712
Hs-CRP [mg/L] 5.61 ± 3.45 8.33 ± 4.69 0.016*
Peak cTnT [μg/L] 6.72 ± 3.70 8.23 ± 5.08 0.188
Peak CK-MB [U/L] 105.75 ± 102.08 144.98 ± 116.25 0.170
Oxidative stress markers:
Malondialdehyde [nmol/L] 5.69 ± 1.84 6.94 ± 1.55 0.029*
Superoxide dismutase [NU/mL] 65.40 ± 12.78 52.20 ± 13.12 0.003**
Nitric oxide [μmol/L] 67.04 ± 29.77 57.57 ± 25.79 0.488
Angiography results:
Left main 1 (2.9%) 6 (23.1%) 0.045*
Single-vessel 11 (32.4%) 4 (15.4%) 0.229
Double-vessel 10 (29.4%) 5 (19.2%) 0.367
Triple-vessel 13 (38.2%) 17 (65.4%) 0.037*
Gensini score 70.61 ± 34.12 81.92 ± 43.29 0.275
Values are expressed as mean ± standard deviation or n (%); *p < 0.05; **p < 0.01; BP — blood pressure; LVEDD — left ventricular end-
diastolic diameter; LVESD — left ventricular end-systolic diameter; LVEF — left ventricular ejection fraction; TC — total cholesterol; TG — tri-
glycerides; LDL-C — low-density lipoprotein cholesterol; HDL-C — high-density lipoprotein cholesterol; APG — admission plasma glucose; 
HbA1c — glycosylated hemoglobin; WBC — white blood cell; ESR — erythrocyte sedimentation rate; hs-CRP — high sensitivity C-reactive 
protein; cTnT — troponin T; CK-MB — creatine kinase isoenzyme MB
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activated in the presence of hyperglycemia, and 
plays an important role in the pathogenesis of DM 
complications. Inhibition of the Rho/ROCK path-
way can ameliorate diabetes-induced microvascu-
lar damage [14]. ROCK is activated in beta cells 
under hyperglycemic conditions and suppression 
of the Rho/ROCK pathway increases insulin gene 
transcription [15]. Hyperglycemia can stimulate 
plasminogen activator inhibitor-1  expression [16], 
which is increased significantly in patients with 
DM or metabolic syndrome who present with MI, 
and was positively correlated with long-term car-
diovascular events. Most studies have focused on 
animal models, and clinical research is still lacking. 
In this study, we showed that ROCK1 activity is 
increased in STEMI patients with DM.
Rho kinase protein expression and ROCK 
activity are enhanced with inflammation, such 
as that present in patients with STEMI. Various 
inflammatory reactions can influence ROCK ex-
pression, but the extent of elevation is obvious in 
STEMI patients with DM. Despite an increase in 
Figure 1. A. Protein activity of Rho kinase (ROCK)1; B. Protein activity of ROCK2. The activity of ROCK1 was signifi-
cantly increased in ST elevation myocardial infarction patients with diabetes (DM) than those without diabetes (NDM), 
and there were no between-group differences regarding the activity of ROCK1.
Figure 2. A. Representative western blots of Rho kinase (ROCK)1 and ROCK2 isoforms in circulating leukocytes in 
ST elevation myocardial infarction (STEMI) patients with and without diabetes; B. Protein expression of ROCK1; 
C. Protein expression of ROCK2. The protein levels of ROCK1 and ROCK2 were greater in STEMI patients with diabetes 
(DM) than those without diabetes (NDM); GADPH — d-glyceraldehyde-3-phosphate dehydrogenase.
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Table 2. Baseline clinical characteristics (including concomitant therapy) between no event and event 
groups.
Characteristic No event (n = 41) Event (n = 19) P
Age [years] 61.47 ± 11.70 62.21 ± 9.50 0.813
Sex (male) 32 (78.0%) 17 (89.5%) 0.287
Medical history:
Hypertension 24 (61.0%) 13 (72.2%) 0.557
Old myocardial infarction 4 (9.8%) 5 (26.3%) 0.126
Stroke 1 (2.4%) 6 (31.6%) 0.003**
Current smoker 8 (21.1%) 6 (31.6%) 0.384
Diabetes mellitus 12 (29.3%) 14 (73.7%) 0.002**
Clinical tests:
Body mass index [kg/m2] 24.72 ± 5.20 25.08 ± 3.84 0.791
Waist circumference [cm] 92.05 ± 10.62 91.79 ± 10.52 0.930
Systolic BP [mm Hg] 124.71 ± 20.42 128.63 ± 18.69 0.485
Diastolic BP [mm Hg] 72.89 ± 11.71 75.58 ± 11.61 0.417
Heart rate [bpm] 77.45 ± 13.80 79.58 ± 14.23 0.589
LVEDD [cm] 5.28 ± 0.39 5.61 ± 0.75 0.094
LVESD [cm] 3.78 ± 0.56 4.18 ± 0.91 0.097
LVEF [%] 54.64 ± 10.24 49.94 ± 11.08 0.128
Gensini score 66.76 ± 40.06 78.58 ± 35.84 0.282
Laboratory tests:
TC [mmol/L] 4.72 ± 0.85 4.53 ± 0.93 0.444
TG [mmol/L] 2.27 ± 1.82 1.48 ± 0.84 0.078
LDL-C [mmol/L] 2.53 ± 0.49 2.45 ± 0.57 0.579
HDL-C [mmol/L] 0.99 ± 0.20 0.96 ± 0.19 0.547
APG [mmol/L] 9.08 ± 3.21 10.24 ± 5.21 0.304
HbA1c [%] 6.49 ± 1.46 7.41 ± 1.76 0.048*
WBC [×109/L] 10.90 ± 3.07 10.35 ± 3.49 0.550
ESR [mm/1 h] 9.27 ± 7.67 12.68 ± 8.03 0.039*
Hs-CRP [mg/L] 6.85 ± 3.80 11.69 ± 3.75 0.538
Peak cTnT [μg/L] 6.47 ± 3.93 9.41 ± 4.78 0.015*
Peak CK-MB [U/L] 114.18 ± 109.09 143.31± 110.69 0.342
ROCK activity:
ROCK1 [μmol NADH/mg·min] 26.92 ± 9.81 34.58 ± 13.62 0.016*
Concomitant therapy:
Aspirin 39 (95.1%) 18 (94.7%) 0.983
Clopidogrel 21 (51.2%) 6 (31.6%) 0.155
Statins 34 (82.9%) 15 (78.9%) 0.711
Beta-blockers 37 (90.2%) 17 (89.5%) 0.926
ACEI/ARB 38 (92.7%) 17 (89.5%) 0.676
Values are expressed as mean ± standard deviation or n (%); *p < 0.05, **p < 0.01; BP — blood pressure; LVEDD — left ventricular end-
diastolic diameter; LVESD — left ventricular end-systolic diameter; LVEF — left ventricular ejection fraction; TC — total cholesterol; TG —  
triglycerides; LDL-C — low-density lipoprotein cholesterol; HDL-C — high-density lipoprotein cholesterol; APG — admission plasma glucose; 
HbA1c — glycosylated hemoglobin; WBC — white blood cell; ESR — erythrocyte sedimentation rate; hs-CRP — high sensitivity C-reactive  
protein; cTnT — troponin T; CK-MB — creatine kinase isoenzyme MB; ROCK — Rho kinase; ACEI/ARB — angiotensin converting enzyme  
inhibitor/angiotensin receptor blocker
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the level of both ROCK1 and ROCK2 protein ex-
pression in STEMI patients with DM, we found that 
only ROCK1 activity was greater compared with 
patients without DM. These findings suggest that 
the activation of ROCK1, rather than the level of 
ROCK1 expression, is the underlying mechanism 
associated with STEMI patients with DM. Further-
more, ROCK1 plays a key role in the pathogenesis 
of atherosclerosis, such as macrophage chemotaxis, 
cholesterol uptake and foam cell formation [17]. 
ROCK1 also mediates neointimal proliferation via 
recruitment of circulating leukocytes and infiltra-
tion of inflammatory cells into the vessel wall [18]. 
Another study showed that ROCK1 is involved 
in the resistance to insulin action on glucose 
disposal in muscle tissue of obese type 2 diabetic 
subjects [19]. Deficiency of ROCK1, with impair-
ment of insulin signaling, causes systemic insulin 
resistance [20] and inhibition of ROCK decreases 
insulin-stimulated glucose uptake and insulin sign-
aling [21]. Thus, the ability of insulin to activate 
ROCK1 is significantly impaired in hyperglycemia, 
further indicating that ROCK1 activity is elevated 
in STEMI patients with DM.
Evidence indicates that the ROCK-mediated 
pathway is involved at all stages of the inflamma-
tory process. Activated ROCK down-regulates 
endothelial NO synthase (eNOS), whereas the 
inhibitor of ROCK rapidly increases endothelial 
eNOS activity [22]. By activating the myosin phos-
phatase, NO itself antagonizes the vasoconstrictor 
effect of ROCK [23]. Our study showed that plasma 
levels of MDA were greater and SOD was lower in 
the DM group. There was no significant between-
group difference in the NO level. Hyperglycemia 
can promote an oxidative stress state, increasing 
lipid peroxide formation, reflected by increased 
MDA levels. However, decreased activity of an-
tioxidant enzymes reduces the body’s ability of 
scavenging free radicals in this condition, which 
results in the decreasing of SOD level. Although 
our study showed that the NO level in DM patients 
was lower, the difference between groups was not 
significant. In our study, hs-CRP was elevated in 
STEMI patients with DM, but we did not find any 
Table 3. Effects of several variables on clinical endpoints using multivariate regression analysis.
Variables Adjusted relative risk 95% confidence interval P
Age 0.973 0.917–1.033 0.367
Sex (male) 1.542 0.307–7.760 0.599
Diabetes mellitus 2.411 0.747–7.777 0.141
Stroke 11.509 2.498–53.037 0.002**
Current smoker 1.098 0.281–4.293 0.893
LVEDD 3.320 0.212–51.863 0.392
LVESD 0.625 0.083–4.693 0.648
Peak troponin T 1.249 1.068–1.460 0.005**
Peak CK-MB 0.995 0.990–1.000 0.067
ROCK1 activity 1.037 1.001–1.075 0.043*
Values are expressed as mean ± standard deviation; *p < 0.05; **p < 0.01; LVEDD — left ventricular end-diastolic diameter; LVESD — left 
ventricular end-systolic diameter; CK-MB — creatine kinase isoenzyme MB; ROCK — Rho kinase
Figure 3. Kaplan-Meier survival curves for cardiovas-
cular events in 60 patients. High Rho kinase (ROCK)1 
activity (above 26.41 μmol NADH/mg × min) has higher 
risk to low ROCK1 activity group (relative risk: 3.15; 
95% confidence interval: 1.04–9.58; log rank = 8.800, 
p = 0.003).
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correlation between ROCK1 activity and inflam-
matory factors. The lack of association between 
ROCK1 and inflammatory factors might spring 
from a small number of subjects in the present 
study.
Rho kinase 1 deletion did not impair com-
pensatory hypertrophic response but significantly 
reduced cardiomyocyte apoptosis and fibrosis in 
response to pressure overload induced by trans-
verse aortic constriction [24]. Another recent 
study showed the long-term beneficial effects of 
ROCK1 deficiency in hypertrophic decompensation 
and suggested that ROCK1 may be an attractive 
therapeutic target to limit heart failure progres-
sion [25]. In this study, the coronary angiography 
results showed that the coronary triple-vessel and 
left main lesion were more frequent in the DM 
group, but the Gensini score was similar between 
groups and the ROCK1 activity did not correlate 
with the Gensini score. We consider that further 
research is needed to clarify these observations. 
Moreover, there were no significant differences in 
echocardiographic dimensions between the groups, 
but patients had lower LVEF in the DM group, with 
lesions of greater severity in the coronary artery 
in the DM group.
ROCK1 activity can identify STEMI  
patients at particularly high risk
Cardiovascular and cerebrovascular diseases 
associated with type 2 diabetes mellitus (T2DM) 
are the most frequent causes of death among 
diabetic patients. Both epidemiological and ex-
perimental studies have shown that the level 
of HbA1c is associated with microvascular and 
vascular complications. For T2DM patients, the 
level of HbA1c increased by 1%, the relative risk 
of CHD increased by 18%, and the relative risk of 
stroke increased by 17% [26]. The United Kingdom 
Prospective Diabetes Study long-term follow-up 
results showed that HbA1c was one of the cardio-
vascular risk factors for patients with CHD [27]. 
Studies have demonstrated that high fasting blood 
glucose and HbA1c may predict fatal and nonfatal 
stroke [28], and actively control blood glucose to 
prevent large vascular complications and improve 
prognosis. The Daqing study included newly 
diagnosed Chinese T2DM patients who were fol-
lowed for 23 years, and found that the cumulative 
incidence of cardiovascular and cerebrovascular 
diseases in China increased [29].
Similarly in our study, HbA1c in the group with 
occurrence of cardiovascular and cerebrovascular 
events was significantly higher than in the non-
event group. HbA1c can reflect the average level 
of blood glucose in patients with DM. We found 
that HbA1c was positively associated with ROCK1 
activity, indicating that patients with severe DM 
may have higher ROCK1 activity. Past history of 
DM or stroke and ROCK1 activity on admission 
were compared between event and non-event 
groups. These factors were all significantly cor-
related with long-term events but DM was not an 
independent predictor. We may have obtained these 
results because our sample size was small and the 
follow-up period was short.
Studies have demonstrated that there is 
a great risk of cardiovascular and cerebrovascular 
disease in patients with stroke. Feske et al. [30] 
demonstrated that ROCK activity increased in 
acute stroke patients, suggesting its role in the 
pathogenesis of acute ischemia. cTnT is of high 
sensitivity and specificity and has become the gold 
standard for clinical diagnosis of acute MI. In the 
guidelines issued by the European and American 
Heart Association, cTnT, as a biochemical marker 
of myocardial cell necrosis, was used to evaluate 
the diagnosis, risk stratification, and prognosis of 
MI. A recent study showed that ROCK activity 
was increased in patients with ACS, particularly 
in those with MI and the combined usage of both 
ROCK activity and NT-proBNP might identify 
ACS patients at particularly high risk [7]. In our 
study, stroke, peak cTnT, and ROCK1 activity were 
independent predictors and strongly correlated 
with future cardiovascular outcomes. This probably 
indicates that ROCK1 activity might be a strong 
predictor of future cardiovascular events.
Limitations of the study
The main limitation of this study is a relatively 
small number of enrolled patients due to one part of 
a series of studies in our group. Because we have 
assessed ROCK activity in leukocytes using pe-
ripheral blood samples, it is possible that circulat-
ing leukocytes do not accurately represent ROCK 
activity within the coronary artery. Additionally, 
a greater understanding of the physiological role 
of each ROCK isoform and the development of 
isoform-specific inhibitor is needed.
Conclusions
In STEMI patients, DM is associated with 
increased ROCK1 activity. ROCK1 activity might 
be a good biomarker to predict long-term cardio-
vascular events. Inhibition of ROCK1 may be 
a potential therapeutic target for DM.
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